Literature DB >> 3698010

Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole.

S Gonzalez, M R Arnfield, B E Meeker, J Tulip, W H Lakey, J D Chapman, M S McPhee.   

Abstract

Fischer X Copenhagen rats bearing Dunning R3327-AT tumors were treated with hematoporphyrin derivative and red light (630 nm from an argon-driven dye laser) alone or in combination with the hypoxic cell radiosensitizer, misonidazole (MISO). In vitro studies had suggested that hypoxia might significantly decrease the cytotoxicity of photodynamic therapy (PDT) and labeling with [14C]MISO had revealed a significant fraction of viable hypoxic cells in this tumor. PDT alone resulted in a growth delay of 8.8 days but no tumor cures were observed. The administration of MISO (i.p. at 0.5 mg/g) 33 min prior to PDT resulted in an average growth delay of 15.2 days and tumor cures (local control at 33 days) in 20% of animals treated. If MISO at a similar dosage was administered 30 min after PDT an average growth delay of 16.3 days was measured and tumor cure was observed in 70% of the animals treated. These results suggest that the hypoxic cell fraction in R3327-AT tumors might be a limitation to their curability by PDT. The addition of MISO and/or other hypoxic cell cytotoxic agents to PDT procedures may provide an effective means of treating PDT-resistant hypoxic cells in solid tumors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698010

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Increased efficacy of photodynamic therapy of R3230AC mammary adenocarcinoma by intratumoral injection of Photofrin II.

Authors:  S L Gibson; K R van der Meid; R S Murant; R Hilf
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

2.  Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo.

Authors:  Qi Xie; Lin Jia; Yan-Hong Liu; Cheng-Gang Wei
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

Review 3.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 4.  Current status of photodynamic therapy in oncology.

Authors:  R van Hillegersberg; W J Kort; J H Wilson
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

5.  Non-invasive monitoring of photodynamic therapy with 99technetium HMPAO scintigraphy.

Authors:  R B Moore; J D Chapman; A D Mokrzanowski; M R Arnfield; M S McPhee; A J McEwan
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

Review 6.  Photodynamic therapy: a new approach to prostate cancer.

Authors:  Rolf Muschter
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

7.  Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.

Authors:  J C Bremner; G E Adams; J K Pearson; J M Sansom; I J Stratford; J Bedwell; S G Bown; A J MacRobert; D Phillips
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

8.  Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study.

Authors:  P Baas; I P van Geel; H Oppelaar; M Meyer; J H Beynen; N van Zandwijk; F A Stewart
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

9.  Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma.

Authors:  L W Ma; J Moan; H B Steen; V Iani
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

10.  Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy.

Authors:  I P van Geel; H Oppelaar; P F Rijken; H J Bernsen; N E Hagemeier; A J van der Kogel; R J Hodgkiss; F A Stewart
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.